Identifying factors and target preventive therapies for Middle East Respiratory Syndrome sucsibtable patients.
Identifieur interne : 000179 ( PubMed/Checkpoint ); précédent : 000178; suivant : 000180Identifying factors and target preventive therapies for Middle East Respiratory Syndrome sucsibtable patients.
Auteurs : Khalid A. Alburikan [Arabie saoudite] ; Hatem A. Abuelizz [Arabie saoudite]Source :
- Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society [ 1319-0164 ] ; 2020.
Abstract
Middle East Respiratory Syndrome (MERS) is a respiratory disease caused by a novel coronavirus that was identified in 2012 in Saudi Arabia. It is associated with significant mortality and morbidity. We identified factors associated with the Middle East Respiratory Syndrome-Coronavirus (MERS-CoV) infection among suspected cases presented with sign and symptoms of upper respiratory infection or exposure to the virus. We also looked at the impact of medication history on virus transmission.
DOI: 10.1016/j.jsps.2019.11.016
PubMed: 32042254
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:32042254Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Identifying factors and target preventive therapies for Middle East Respiratory Syndrome sucsibtable patients.</title><author><name sortKey="Alburikan, Khalid A" sort="Alburikan, Khalid A" uniqKey="Alburikan K" first="Khalid A" last="Alburikan">Khalid A. Alburikan</name><affiliation wicri:level="1"><nlm:affiliation>Department of Clincal Pharmacy, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Department of Clincal Pharmacy, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451</wicri:regionArea><wicri:noRegion>Riyadh 11451</wicri:noRegion></affiliation></author><author><name sortKey="Abuelizz, Hatem A" sort="Abuelizz, Hatem A" uniqKey="Abuelizz H" first="Hatem A" last="Abuelizz">Hatem A. Abuelizz</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451</wicri:regionArea><wicri:noRegion>Riyadh 11451</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32042254</idno><idno type="pmid">32042254</idno><idno type="doi">10.1016/j.jsps.2019.11.016</idno><idno type="wicri:Area/PubMed/Corpus">000243</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000243</idno><idno type="wicri:Area/PubMed/Curation">000243</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000243</idno><idno type="wicri:Area/PubMed/Checkpoint">000179</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000179</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Identifying factors and target preventive therapies for Middle East Respiratory Syndrome sucsibtable patients.</title><author><name sortKey="Alburikan, Khalid A" sort="Alburikan, Khalid A" uniqKey="Alburikan K" first="Khalid A" last="Alburikan">Khalid A. Alburikan</name><affiliation wicri:level="1"><nlm:affiliation>Department of Clincal Pharmacy, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Department of Clincal Pharmacy, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451</wicri:regionArea><wicri:noRegion>Riyadh 11451</wicri:noRegion></affiliation></author><author><name sortKey="Abuelizz, Hatem A" sort="Abuelizz, Hatem A" uniqKey="Abuelizz H" first="Hatem A" last="Abuelizz">Hatem A. Abuelizz</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451</wicri:regionArea><wicri:noRegion>Riyadh 11451</wicri:noRegion></affiliation></author></analytic><series><title level="j">Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society</title><idno type="ISSN">1319-0164</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Middle East Respiratory Syndrome (MERS) is a respiratory disease caused by a novel coronavirus that was identified in 2012 in Saudi Arabia. It is associated with significant mortality and morbidity. We identified factors associated with the Middle East Respiratory Syndrome-Coronavirus (MERS-CoV) infection among suspected cases presented with sign and symptoms of upper respiratory infection or exposure to the virus. We also looked at the impact of medication history on virus transmission.</div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32042254</PMID><DateRevised><Year>2020</Year><Month>04</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1319-0164</ISSN><JournalIssue CitedMedium="Print"><Volume>28</Volume><Issue>2</Issue><PubDate><Year>2020</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society</Title><ISOAbbreviation>Saudi Pharm J</ISOAbbreviation></Journal><ArticleTitle>Identifying factors and target preventive therapies for Middle East Respiratory Syndrome sucsibtable patients.</ArticleTitle><Pagination><MedlinePgn>161-164</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jsps.2019.11.016</ELocationID><Abstract><AbstractText Label="Background" NlmCategory="UNASSIGNED">Middle East Respiratory Syndrome (MERS) is a respiratory disease caused by a novel coronavirus that was identified in 2012 in Saudi Arabia. It is associated with significant mortality and morbidity. We identified factors associated with the Middle East Respiratory Syndrome-Coronavirus (MERS-CoV) infection among suspected cases presented with sign and symptoms of upper respiratory infection or exposure to the virus. We also looked at the impact of medication history on virus transmission.</AbstractText><AbstractText Label="Method" NlmCategory="UNASSIGNED">We included subjects with suspected MERS-CoV infection and confirmed cases of MERS infection. Subjects were excluded if there were any missing data that prevent the final analysis. Descriptive statistics were used to report demographic data. Percentages and frequencies were used to summarize the categorical variables, while means and standard deviations were calculated for continuous variables. Logistic regression was used to assess the risk of MERS-CoV infection among the suspected cases. A value of <i>p</i> < 0.05 was considered statistically significant.</AbstractText><AbstractText Label="Results" NlmCategory="UNASSIGNED">A total of 16,189 suspected cases were identified, complete data were analyzed for 3154 to assess factors that are independently associated with MERS-CoV infection. MERS-CoV infection was associated with age (adjusted odds ratio [AOR] = 1.06; 95% CI [1.02-1.098], P-value = 0.004), male gender (AOR = 1.617; 95% CI [1.365-1.77], P-value < 0.001) and diabetes (AOR = 1.68; 95% CI [1.346-1.848], P-value = 0.002. There was no significant association with the other comorbidities. Medication history was not associated with an increase or decrease the likelihood of the infection.</AbstractText><AbstractText Label="Conclusions" NlmCategory="UNASSIGNED">MERS-Cov infection is more common in male, advanced age and diabetes. No medications were associated with an increase or decrease the likelihood of the infection. This is important to focus on screening and detection to this patient population.</AbstractText><CopyrightInformation>© 2019 Published by Elsevier B.V. on behalf of King Saud University.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alburikan</LastName><ForeName>Khalid A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Department of Clincal Pharmacy, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abuelizz</LastName><ForeName>Hatem A</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>12</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Saudi Arabia</Country><MedlineTA>Saudi Pharm J</MedlineTA><NlmUniqueID>9705695</NlmUniqueID><ISSNLinking>1319-0164</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Diabetes</Keyword><Keyword MajorTopicYN="N">MERS-CoV</Keyword><Keyword MajorTopicYN="N">Middle East Respiratory Syndrome</Keyword></KeywordList><CoiStatement>The authors declare no potential conflicts of interest withrespect to the research, authorship, and publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>05</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32042254</ArticleId><ArticleId IdType="doi">10.1016/j.jsps.2019.11.016</ArticleId><ArticleId IdType="pii">S1319-0164(19)30166-5</ArticleId><ArticleId IdType="pmc">PMC7000305</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>BMC Infect Dis. 2017 Jan 5;17(1):23</Citation><ArticleIdList><ArticleId IdType="pubmed">28056850</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2013 Jun 29;381(9885):2265-72</Citation><ArticleIdList><ArticleId IdType="pubmed">23727167</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Emerg Microbes Infect. 2017 Jun 7;6(6):e51</Citation><ArticleIdList><ArticleId IdType="pubmed">28588290</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 2013 Mar 14;495(7440):251-4</Citation><ArticleIdList><ArticleId IdType="pubmed">23486063</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2013 Aug 1;369(5):407-16</Citation><ArticleIdList><ArticleId IdType="pubmed">23782161</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2015 Sep 5;386(9997):995-1007</Citation><ArticleIdList><ArticleId IdType="pubmed">26049252</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Am J Epidemiol. 2016 Sep 15;184(6):460-4</Citation><ArticleIdList><ArticleId IdType="pubmed">27608662</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2013 Dec 14;382(9909):1993-2002</Citation><ArticleIdList><ArticleId IdType="pubmed">24055451</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clin Microbiol Rev. 2015 Apr;28(2):465-522</Citation><ArticleIdList><ArticleId IdType="pubmed">25810418</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2013 Jul;87(14):7790-2</Citation><ArticleIdList><ArticleId IdType="pubmed">23678167</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Arabie saoudite</li></country></list><tree><country name="Arabie saoudite"><noRegion><name sortKey="Alburikan, Khalid A" sort="Alburikan, Khalid A" uniqKey="Alburikan K" first="Khalid A" last="Alburikan">Khalid A. Alburikan</name></noRegion><name sortKey="Abuelizz, Hatem A" sort="Abuelizz, Hatem A" uniqKey="Abuelizz H" first="Hatem A" last="Abuelizz">Hatem A. Abuelizz</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000179 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000179 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:32042254
|texte= Identifying factors and target preventive therapies for Middle East Respiratory Syndrome sucsibtable patients.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:32042254" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |